Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Takeda HQ
Takeda recently shifted its headquarters to Boston from its old Chicago-area HQ, pictured here. (Takeda)

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy is Takeda's next-gen cell therapies, and the company is now doubling down to get those products to market. 

Takeda has opened a 24,000-square-foot R&D manufacturing center in Boston as the Japanese drugmaker works to flesh out a bustling cell therapy pipeline focused immediately on immuno-oncology, Takeda said Tuesday.

The newest facility, part of Takeda's pivot to Boston for its U.S. operations, will handle clinical development for three ongoing pipeline programs and two other projects expected to enter clinical development by the end of 2021, the drugmaker said. 

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The slate of projects currently in development includes TAK-007, a phase 1/2 chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy that Takeda is studying to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. 

Takeda also two CAR-T therapies in the pipe: TAK-940, a Memorial Sloan Kettering Cancer Center-partnered therapy to treat relapsed/refractory B-cell cancers; and TAK-102, a solid-tumor hunter developed alongside Noile-Immune Biotech. 

While Takeda's focus will initially be on its I-O pipeline, the drugmaker could eventually expand its efforts out to cell therapies beyond cancer, the company said.

RELATED: Goodbye, Chicago: Takeda sets December deadline for U.S. employees' Boston move

RELATED: Takeda whittles away costs—and assets—to keep its debt-cutting promises

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.